BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  TG Therapeutics Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting

  The following summarizes the highlights from each poster presented at the ASH 2017 meeting.

  December 11, 2017

   · 

  9 min read
• Business

  Exscientia Appoints Alex Snow, Founder of Oxford Innovation Sciences and Former CEO of Lansdowne Partners, as Deputy Chairman

  Exscientia, the innovative company at the forefront of AI-driven drug discovery, is pleased to announce the appointment of Mr Alex Snow to its Board of Directors as Deputy Chairman.

  December 11, 2017

   · 

  1 min read
• Drug Development

  Innovation Pharmaceuticals Reports Positive Topline Results from Phase II Placebo-Controlled Trial of Brilacidin for the Prevention of Oral Mucositis in Head and Neck Cancer Patients

  Brilacidin-OM is being developed under an FDA Fast Track designation for this indication.

  December 11, 2017

   · 

  10 min read
• Business

  Abzena Secures Contract for Integrated ADC Manufacturing Services to U.S. Biotech Company

  Abzena has entered into a Master Services Agreement with a U.S. biotech company to provide process development and manufacturing services to progress a novel ADC towards clinical trials.

  December 11, 2017

   · 

  3 min read
• Business

  Medigene Collaborates With RXi Pharma to Further Sharpen its Therapeutic T cells

  The preclinical research program will examine the applicability of RXi’s sd-rxRNA technology to be integrated into Medigene’s process to produce receptor-modified T cells with the ultimate goal to further improve Medigene’s T cell therapies for the treatment of cancer patients.

  December 11, 2017

   · 

  6 min read
• Pharm Country

  OncoTartis Closes $6M Financing Round

  OncoTartis has concluded a $6M financing round to support the Phase 1 clinical trial of its lead drug candidate, OT-82.

  December 11, 2017

   · 

  2 min read
• Business

  Cardiome Highlights Partner SteadyMed’s Agreement With FDA on Pathway to Trevyent NDA Resubmission

  Cardiome plans to submit regulatory filings for Trevyent in Europe and Canada shortly following SteadyMed’s NDA resubmission to the FDA.

  December 11, 2017

   · 

  7 min read
• Drug Development

  Caris Life Sciences Identifies New Mechanism of Action for an Aptamer With Therapeutic Potential to Treat Non-Hodgkin Lymphoma

  Results of this study showed that C10.36 binding to cell-surface hnRNP U resulted in internalization of the complex, disruption of pre-mRNA splicing and cell death in a subset of NHL cell lines in vitro.

  December 11, 2017

   · 

  3 min read
• Business

  Boehringer Ingelheim Marks Great Progress in Immuno-Oncology Research Partnerships in 2017

  External partnerships complement Boehringer Ingelheim’s two-pronged research strategy - investigating both cancer cell-directed therapies and immune cell-directed therapies.

  December 11, 2017

   · 

  5 min read
• Policy

  Janssen Submits Supplemental NDA to FDA Seeking New Indications for XARELTO (rivaroxaban) for Patients With Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)

  This application is based on data from the landmark COMPASS study, the only randomized trial to investigate a Factor Xa inhibitor for preventing major CV events in this population.

  December 11, 2017

   · 

  12 min read